Antibody Drug Conjugate Development & Testing

Accelerate Your Drug Discovery With Southern Research

SR-ADC-Hero-1

Antibody Drug Conjugate Development & Testing

Southern Research is a leading contract research organization (CRO) that specializes in the development and testing of ADCs. We have a team of experienced scientists and researchers who are experts in all aspects of ADC development, including:

  • Design and synthesis of ADC linker molecules
  • Conjugation of linker molecules to antibodies and cytotoxic drugs
  • Characterization of ADCs
  • In vitro and in vivo testing of ADCs
  • Assessment of the safety and efficacy of ADC

We offer a comprehensive range of ADC development and testing services, including:

  • Feasibility studies: We can help you assess the feasibility of developing an ADC for your target disease.
  • Lead optimization: We can help you optimize your ADC lead compound to improve its safety and efficacy.
  • Preclinical testing: We can conduct all of the necessary preclinical testing to evaluate the safety and efficacy of your ADC drug candidate in animal models.
  • Manufacturing development: We can help you develop a manufacturing process for your ADC drug candidate so that it can be produced at scale for clinical trials.

Targeted Cancer Therapies

If you are developing an ADC drug candidate, we encourage you to contact us to learn more about how we can help you accelerate your drug development.

Antibody drug conjugates (ADCs) are a type of targeted cancer therapy that combines the targeting specificity of antibodies with the potency of cytotoxic drugs. ADCs are made up of three components:

    • An antibody that specifically binds to a tumor marker on cancer cells
    • A cytotoxic drug that kills cancer cells
    • A linker that connects the antibody to the cytotoxic drug

Once an ADC is injected into the bloodstream, it travels to the tumor and binds to the tumor marker. The ADC then enters the cancer cell and releases the cytotoxic drug, which kills the cancer cell.

ADCs are a promising new class of cancer therapy because they are more targeted and less toxic than traditional chemotherapy drugs. ADCs can also be used to treat cancer cells that have become resistant to other types of therapy.

ADCs are still under development, but they have the potential to revolutionize the treatment of cancer. Here are some of the advantages of ADCs:

    • ADCs are more targeted than traditional chemotherapy drugs, which means that they are less likely to harm healthy cells.
    • ADCs are effective against cancer cells that have become resistant to other types of therapy.
    • ADCs can be used to deliver cytotoxic drugs to cancer cells that are difficult to reach with other types of therapy.

Overall, ADCs are a promising new class of cancer therapy with the potential to improve the lives of many patients

Basic Template Image

© 2024 Southern Research. All rights reserved.